Search Results - "Udrea, Adrian A."

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial by Wainberg, Zev A., Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian A., Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter C.

“…Background We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for…”
Get full text

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study by Wainberg, Zev A, Enzinger, Peter C, Kang, Yoon-Koo, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Borg, Christophe, Hitre, Erika, Udrea, Adrian A, Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Collins, Helen, Mitra, Siddhartha, Yang, Yingsi, Catenacci, Daniel V T, Lee, Keun-Wook

“…Outcomes are poor in patients with HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinomas. In this study, we investigated efficacy and…”
Get full text